Results 1 to 10 of about 3,538 (271)

Blueprint for antibody biologics developability

open access: yesMAbs, 2023
Large-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review, we focus on
Yanling Wang, Xuejin Zhang
exaly   +4 more sources

Developability considerations for bispecific and multispecific antibodies

open access: yesMAbs
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash   +9 more
exaly   +4 more sources

Assessing developability early in the discovery process for novel biologics [PDF]

open access: yesMAbs, 2023
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures.
Guy Georges   +2 more
exaly   +6 more sources

Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler [PDF]

open access: yesCommunications Biology
Developability optimisation is an important step for successful biotherapeutic design. For monoclonal antibodies, developability is relatively well characterised. However, progress for novel biotherapeutics such as nanobodies is more limited. Differences
Gemma L. Gordon   +3 more
doaj   +3 more sources

Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics

open access: yesMAbs, 2022
Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly ...
Kouhei Tsumoto   +2 more
exaly   +2 more sources

Application of protein language models for antibody developability prediction [PDF]

open access: yesmAbs
Protein language models (PLMs) provide a powerful framework for learning sequence – property relationships in antibodies. However, their performance and reliability in real-world industrial antibody discovery pipelines remain underexplored.
Samad Amini   +5 more
doaj   +2 more sources

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training [PDF]

open access: yesmAbs
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g.
Ammar Arsiwala   +27 more
doaj   +2 more sources

Developability Evaluation of Single-Domain Antibody-Chelator Conjugates for Diagnostic Radiotracers [PDF]

open access: yesAntibodies
Background/Objectives: Developability assessment is a critical step in advancing antibody-based molecules toward clinical application. This evaluation typically begins during clinical candidate selection and continues throughout all modifications of the ...
Philipp D. Kaiser   +5 more
doaj   +2 more sources

Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation [PDF]

open access: yesmAbs
Antibody therapeutics are a rapidly growing class of biopharmaceuticals, but concerns regarding potential developability issues persist. While complementarity-determining region (CDR) loops are imperative for antigen specificity and mutations are ...
Vera A. Spanke   +9 more
doaj   +2 more sources

Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

open access: yesMAbs, 2023
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2.
Gilad Kaplan, Song Ren, Andrew Garcia
exaly   +3 more sources

Home - About - Disclaimer - Privacy